Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Coronavirus / COVID-19 Pandemic -- Ignore unavailable to you. Want to Upgrade?

To: Investor2 who wrote (18601)	10/28/2021 7:47:57 PM
From: Thomas M.	Respond to of 22868

"For 2500 years we’ve known about natural immunity. It is stronger and longer-lasting than if you have a vaccine. Hospitals should hire nurses and staff with natural immunity. But we are doing the opposite, they are being fired." - Harvard Medical School Professor Martin Kulldorff "For ~2500yrs we’ve known about natural immunity.. It is stronger & longer-lasting than if you have a vaccine. Hospitals should hire nurses/staff with natural immunity.. And we are doing the opposite, they are being fired..." —Harvard Prof @MartinKulldorff pic.twitter.com/xtk9E549Vx — Kulvinder Kaur MD (@dockaurG) October 28, 2021 Tom

To: Investor2 who wrote (18601)	10/28/2021 7:58:27 PM
From: Savant	1 Recommendation Recommended By Glenn Petersen Respond to of 22868

I2,,,just a writer trying to be clever, most likely...I'd be more skeptical if it said..."It's a buncha Horse Pucky " %Col. Potter First published in JAMA in November 2020. A parallel study run by Hoertel and other French researchers also found that hospitalized COVID patients who were prescribed fluvoxamine had a lower risk of being intubated or dying. This led to fluvoxamine’s selection for the TOGETHER trial—the largest double-blind, randomized clinical trial to date to study the efficacy of eight pre-existing drugs against COVID-19. The fluvoxamine arm of the trial began in January 2021 and involved giving the drug to 741 COVID-positive Brazilian adults who were unvaccinated and were deemed high-risk for severe infection. Another 756 COVID-positive participants were given a placebo.